CD20xCD3
![Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL](https://pharmtales.com/wp-content/uploads/2023/06/Glofitamab-gxbm-receives-FDA-approval-for-relapsing-or-resistant-DLBCL.jpg)
Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL
SG Tylor
Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...
Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...